![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen to Present at the JP Morgan Healthcare Conference
04 janv. 2010 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in the 28th Annual JP Morgan Healthcare Conference...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen to Present at the 63rd Annual Meeting of the American Epilepsy Society
01 déc. 2009 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to the Company's Phase I program for ICA-105665, the Company's lead drug...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Reports Receipt of Notification from NASDAQ Regarding Non-Compliance With Continued Listing Requirements
13 nov. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today that on November 12, 2009 the Company received a notification from the NASDAQ Listing...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Reports Third Quarter 2009 Financial Results and Operational Highlights
05 nov. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today its financial results and operational highlights for the third quarter ended September 30,...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Reports Top-line Results of Phase IIa Study of Senicapoc in Exercise-Induced Asthma
26 oct. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen to Report Third Quarter 2009 Results on November 5, 2009
26 oct. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced plans to release third quarter 2009 financial results on Thursday, November 5, 2009 before...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen to Present at Eighth Annual Bio Investor Forum
20 oct. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in the Eighth Annual BIO Investor Forum to be held...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Describes Progress in Its Collaboration With Pfizer to Identify Selective Sodium Channel Inhibitors
19 oct. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to its collaboration with Pfizer focused on certain sodium channels for the...
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Announces Initiation of Proof-of-Mechanism Study of ICA-105665 in Pain
28 sept. 2009 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a proof-of-mechanism study of ICA-105665 for the treatment of pain....
![Icagen, Inc. Logo](/news-release/logo/217869/0/217869.jpg?lastModified=12%2F09%2F2016%2023%3A18%3A31&size=2)
Icagen Announces Initiation of Proof-of-Concept Study of ICA-105665 in Photosensitive Epilepsy
24 sept. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a proof-of-concept study of ICA-105665 in patients with photosensitive...